Related Experiment Videos

Proposed MHRA changes to UK children's paracetamol dosing recommendations: modelling study

Sally Eyers1, James Fingleton, Kyle Perrin

  • 1Medical Research Institute of New Zealand, Wellington 6021, New Zealand.

Journal of the Royal Society of Medicine
|May 24, 2012
PubMed

Insights

The proposed MHRA dosing system for paracetamol in children significantly reduces overdose risks compared to current UK guidelines. This change ensures safer paracetamol administration for children of all ages and weights.

Area of Science:

  • Pediatric Pharmacology
  • Drug Safety and Regulation
  • Evidence-Based Medicine

Background:

  • Paracetamol is a common medication for children.
  • Concerns exist regarding paracetamol overdose risks with current UK age-based dosing.
  • The British National Formulary for Children (BNFC) guidelines have been implicated in potential overdosing.

Purpose of the Study:

  • To evaluate the safety of revised UK paracetamol dosing recommendations from the MHRA.
  • To compare the proposed MHRA system against existing product dosing instructions.
  • To assess the potential for reducing paracetamol overdose in pediatric populations.

Main Methods:

  • A theoretical comparison was conducted between the MHRA's proposed dosing system and current UK paracetamol product dosing instructions.
  • A previously validated model was used to compare these dosing recommendations.
  • Single and cumulative daily paracetamol doses were calculated for various weight centiles (9th, 50th, 91st) across different age groups (3 months, 1, 6, and 12 years).

Main Results:

  • Current UK dosing instructions place underweight children at approximately double the recommended paracetamol dose, especially at ages 1 and 6.
  • The proposed MHRA dosing system effectively mitigates this risk.
  • Underweight, average weight, and overweight children receive doses within or marginally above recommended limits with the MHRA system.

Conclusions:

  • The MHRA's proposed paracetamol dosing recommendations enhance child safety by minimizing overdose risks.
  • These revised guidelines offer a safer alternative to current product dosing instructions for pediatric paracetamol use.
  • The new system demonstrates effectiveness across all pediatric age and weight groups.
Abstract

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...